biostudies-literatureUnknown12McNally CJ<h4>Background</h4>Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies.<h4>Materials and methods</h4>Serum samples and clinical information were collected from <i>N</i> = 125 age-matched patients (<i>n</i> = 61 non-PCa and <i>n</i> = 64 PCa) and analyzed using Biochip Array Technology on high-sensitivity cytokine array I (IL-2, IL-4, IL-6, IL-8, IL-10, IL-1α, IL-1β, TNFα, MCP-1, INFγ, EGF, and VEGF), cerebral array II (CRP, D-dimer, neuron-specific enolase, and sTNFR1), and tumor PSA onFrontiers in oncology837127https://www.ebi.ac.uk/biostudies/studies/S-EPMC9161691biostudies-literatureA Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer.PMC9161691Watt JLamont JVPandha HRuddock MWFitzgerald PMcNally CJKurth MJMcKenna DJMoore TfalseA Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer.<h4>Background</h4>Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies.<h4>Materials and methods</h4>Serum samples and clinical information were collected from <i>N</i> = 125 age-matched patients (<i>n</i> = 61 non-PCa and <i>n</i> = 64 PCa) and analyzed using Biochip Array Technology on high-sensitivity cytokine array I (IL-2, IL-4, IL-6, IL-8, IL-10, IL-1α, IL-1β, TNFα, MCP-1, INFγ, EGF, and VEGF), cerebral array II (CRP, D-dimer, neuron-specific enolase, and sTNFR1), and tumor PSA on2022-01-01T00:00:00Z20222025-04-04T13:18:25.931Z2024-11-09T08:40:58.293ZS-EPMC91616913566474710.3389/fonc.2022.837127